AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

The MHRA has approved aumolertinib for adult patients with non-small cell lung cancer (NSCLC), following a groundbreaking ...

While the approval is a historic event for the BiTE drug class in solid tumours, the market share opportunity is restricted ...

Daiichi Sankyo Company Limited (OTC:DSNKY) and AstraZeneca (NASDAQ:AZN) announced promising results from 3 clinical trials: ...

Helena Yu, MD, discusses the importance of zipalertinib's oral administration route for patients with EGFRm non–small cell lung cancer.

Despite its success in advanced melanoma, Bristol Myers Squibb’s fixed-dose PD-1/LAG-3 combo, Opdualag, failed to move the ...

Chemoimmunotherapy offers greater benefits than harms as first-line treatment for older patients with NSCLC, data suggest.

This priority review designation for sevabertinib in previously treated HER2-mutant non–small cell lung cancer is supported ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

The leading PD-1+ NSCLC Companies such as Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others. Promising PD-1+ ...